PX1 Research has launched a new line of US-manufactured sublingual peptide strips for needle-free research applications, featuring formulations of Retatrutide, Tirzepatide, and BPC-157. This development signals a shift in how academic and institutional researchers can access peptide compounds, moving away from injectable formats toward a non-invasive oral delivery method produced under domestic quality control standards.
The strips are manufactured in the United States under current Good Manufacturing Practice (cGMP) protocols, ensuring rigorous quality control throughout production. Each batch undergoes High-Performance Liquid Chromatography (HPLC) purity verification, confirming 99% or greater purity across all formulations. Researchers receive a Certificate of Analysis with each product, providing documented evidence of batch composition before use. The domestic manufacturing approach emphasizes supply chain transparency, which is critical for institutions requiring documentation trails that trace production conditions.
Among the available formulations, dissolving Retatrutide strips have drawn particular attention given the compound's role in ongoing metabolic and weight regulation research. Tirzepatide and BPC-157 are also included, extending coverage to compounds associated with glucose regulation and tissue repair research, respectively. The sublingual delivery format allows the strip to dissolve under the tongue, enabling absorption without needles or syringes. This addresses a logistical gap for research environments where non-invasive administration is required due to protocol specifications, institutional review considerations, or participant-facing study designs.
The full product line is accessible through PX1 Research, with specific information on the dissolving Retatrutide strips available directly on the product page. These sublingual peptide strips are designed for academic and institutional research contexts only and are not intended for clinical, therapeutic, or human consumption. The inclusion of BPC-157 alongside GLP-1 receptor agonist-class compounds such as Retatrutide and Tirzepatide indicates that the line serves a range of research disciplines, with each formulation adapted to accommodate specific stability and absorption characteristics.
The introduction of these needle-free peptide strips is significant because it provides researchers with a non-invasive alternative that may simplify study protocols and reduce procedural complications associated with injectable administration. As the research community continues to explore compounds like Retatrutide, the availability of domestically manufactured, purity-verified sublingual strips could broaden the scope of feasible studies, particularly those involving human participants where needle aversion or ethical considerations arise.
